Torsion dystonia

Summary

Torsion dystonia (MONDO:0044843) is a disease. A subtype of dystonic disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	torsion dystonia
Mondo ID	MONDO:0044843
SNOMED CT	431034009
UMLS	C0013423
MedGen	3941
GARD	0027978
Is cancer (heuristic)	no

Also known as: torsion dystonia

Disease family

This is a subtype of dystonic disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › movement disorder › extrapyramidal and movement disease › dystonic disorder › torsion dystonia

Related subtypes (7): focal dystonia, multifocal dystonia, segmental dystonia, hemidystonia-hemiatrophy syndrome, nocturnal paroxysmal dystonia, inherited dystonia, idiopathic torsion dystonia

Subtypes (1): acquired torsion dystonia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.